drugset / Trial / NCT06787976
Effect of Dolutegravir Compared With Darunavir/Cobicistat on the Severity of Neuropsychiatric Effects al 12 Weeks in Antirretroviral Treatment-Naive Adults.
RandomizedParallel-groupOpen-labelScreening
Summary
This clinical trial aimed at evaluating changes in neuropsychiatric scales for depression, anxiety, insomnia, and sleep quality in people living with HIV (PLHIV) who initiate antiretroviral therapy (ART) with a regimen of Dolutegravir (DTG) or Darunavir/Cobicistat (DRV/c), both combined with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC).
Timeline
- Start
- 2025-06-19
- Primary completion
- 2025-12-21
- Completion
- 2026-01-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Darunavir/Cobicistat | Unknown | — | — |
| Subject | Dolutegravir | Other / unclassified | — | — |